Treatment of vascular risk factors is associated with slower decline in Alzheimer disease
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: There is growing evidence that vascular risk factors (VRF) contribute to cognitive decline. Whether their treatment can slow down the progression of Alzheimer disease (AD) remains unsettled. The aim of this observational study was to evaluate whether the treatment of VRF is associated with a slower cognitive decline in patients who have AD without cerebrovascular disease (CVD). METHODS: We recruited 301 consecutive patients who had AD without CVD (mean age 71.7 years; 69.4% women; first Mini-Mental State Examination [MMSE] mean score 21.6; mean follow-up 2.3 years), who had attended a memory clinic between 1997 and 2003. VRF sought were high blood pressure, dyslipidemia, diabetes mellitus, tobacco smoking, and atherosclerotic disease. Only 21 patients (7.0%) had no VRF. Others were classified as having no VRF treated (n = 72; 25.7%), some VRF treated (n = 119; 42.5%), or all VRF treated (n = 89; 31.8%). We compared MMSE progression over time among these 3 groups using a mixed random effects regression model. RESULTS: Baseline MMSE scores were similar in the 3 groups. With adjustment for confounding factors, MMSE progression over time differed significantly between groups (p = 0.002). Patients with all their VRF treated declined less than those with none of their VRF treated. Those with some VRF treated tended to have an intermediate decline. CONCLUSIONS: In patients who have Alzheimer disease without CVD, treatment of vascular risk factors (VRF) is associated with a slower decline in Mini-Mental State Examination score. Randomized controlled trials are needed to confirm this association, but our data suggest that dementia should not prevent treatment of VRF.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“and may delay disease progression (Deschaintre et al., 2009), at least early in the disease course (Richard et al., 2010).”
From The Pathobiology of Vascular Dementia (2013) · cites this paper as Deschaintre et al., 2009
In the citing paper
“The new 2018 NIA-AA research framework dissociates AD symptoms or phenotypes from the pathologic process.”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [2]
In the citing paper
“Of individuals age 70 years or older, 20% to 40% without cognitive impairment have biomarker or autopsy evidence of AD pathology 2”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [2]
In the citing paper
“It defines AD, for research purposes, purely in terms of a biopathologic construct with the AD biomarkers of amyloid, tau, and neurodegeneration (ATN) criteria, which aids in defining the disease stages. 2”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [2]
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
The central role of the propensity score in observational studies for causal effects
ROSENBAUM, P. R., & RUBIN, D. B. (1983) · Biometrika · doi:10.1093/biomet/70.1.41 · Cited by 31,241
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Global prevalence of dementia: a Delphi consensus study
Ferri, C. P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K., Hasegawa, K., Hendrie, H., Huang, Y., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67889-0 · Cited by 5,332
Román, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia, J. H., Amaducci, L., Orgogozo, J.-M., Brun, A., Hofman, A., et al. (1993) · Neurology · doi:10.1212/wnl.43.2.250 · Cited by 4,921
McKeith, I. G., Galasko, D., Kosaka, K., Perry, E. K., Dickson, D. W., Hansen, L. A., Salmon, D. P., Lowe, J., Mirra, S. S., Byrne, E. J., et al. (1996) · Neurology · doi:10.1212/wnl.47.5.1113 · Cited by 3,960
Estimating Causal Effects from Large Data Sets Using Propensity Scores
Rubin, D. B. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-8_part_2-199710151-00064 · Cited by 2,877
Brookmeyer, R., Gray, S., & Kawas, C. (1998) · American Journal of Public Health · doi:10.2105/ajph.88.9.1337 · Cited by 1,787
15-year longitudinal study of blood pressure and dementia
Skoog, I., Nilsson, L., Persson, G., Lernfelt, B., Landahl, S., Palmertz, B., Andreasson, L.-A., Odén, A., & Svanborg, A. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90608-x · Cited by 1,726
Kivipelto, M., Helkala, E.-L., Laakso, M. P., Hänninen, T., Hallikainen, M., Alhainen, K., Soininen, H., Tuomilehto, J., & Nissinen, A. (2001) · BMJ · doi:10.1136/bmj.322.7300.1447 · Cited by 1,618
Cited by
Items 201–237 of 237
Harrison, B. E. (2011) · Evidence-Based Nursing · doi:10.1136/ebn1151
“which found that pre-existing dementia is frequent in patients with ICH and may be the consequence of neurodegeneration and cerebral amyloid angiopathy.”
BackgroundVascular Cognitive Impairment: An Overview
O'Brien, J. T. (2011)
Zu strikte Senkung des Blutdrucks bei Demenz prognostisch schädlich
Fritschka, E. (2015) · Info Diabetologie · doi:10.1007/s15034-015-0630-1
“Der Gebrauch von Antihypertensiva hatte in einer weiteren Studie auch einen schützenden E¡ekt gehabt [4].”
BackgroundTreatment of vascular risk factors
Hanyu, H. (2012) · Nippon Ronen Igakkai Zasshi Japanese Journal of Geriatrics · doi:10.3143/geriatrics.49.284
10. Dementia Prevention by Best Medical Treatment
Abe, K. (2014) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.103.119a
Cognitive consequences of cerebral small vessel disease
Ferro, J. M., Verdelho, A., & Madureira, S. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781139382694.020 · Cited by 2
Hoffmann, M. W. (2016) · Springer eBooks · doi:10.1007/978-3-319-33181-2_12
Present status and future perspectives for vascular cognitive impairment
Tomimoto, H. (2015) · Nosotchu · doi:10.3995/jstroke.10303
10. Dementia Prevention by Best Medical Treatment
Abe, K. (2014) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.103.2292
Fortschritte in der Demenztherapie – Was ist bereits praxisrelevant?
Röeben, B., Zieschang, T., & Maetzler, W. (2018) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0043-113619
“Dies ist für die Alzheimer-, vaskuläre, Mischund Parkinson-Demenz nachhaltig gezeigt worden [1], gilt aber vermutlich für alle Demenzformen.”
BackgroundGenetic Overlap and Causal Mediation Relationship Between Psychiatric and Non-Psychiatric Phenotypes
Lin, K. (2018) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Cerebrovascular Atherosclerosis: Cognitive Dysfunction Progress and Autophagic Regression
Cho, K., & Kim, G. W. (2018) · InTech eBooks · doi:10.5772/intechopen.72296
“Some evidence has suggested that vascular risk factors are associated with the onset and progression of AD [77].”
BackgroundLifestyle improvement or anti-dementia drugs in Alzheimer’s disease
Niwa, F., Mizuno, T., & Nakagawa, M. (2019) · Current Medical Research and Opinion · doi:10.1080/03007995.2019.1579556
Influence des facteurs de risque vasculaires et de leur traitement sur la cognition
Leys, D., Bombois, S., & Bordet, R. (2017) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)30469-8
Self-citationChen, Y. S. (2018) · theses.fr (ABES) · doi:10.70675/add1c75dzdb73z46dezac5fza0b3b19367da · Cited by 1
Murphy, A. J., Williamson, J. B., & Lamb, D. G. (2019) · Springer eBooks · doi:10.1007/978-3-319-69892-2_677-1
Rusanen, M. (2013) · UEF eRepo (University of Eastern Finland) · Cited by 3
Significance of nanosomes for diagnosis of Alzheimer’s disease
Raja, N., Karuppiah, H., & Easwaran, M. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821013-0.00010-6
Management of Vascular Risk Factors in Dementia
Verdelho, A., & Gonçalves‐Pereira, M. (2021) · Springer eBooks · doi:10.1007/978-3-030-77904-7_8 · Cited by 1
Murphy, A. J., Williamson, J. B., & Lamb, D. G. (2021) · Springer eBooks · doi:10.1007/978-3-030-22009-9_677
Current awareness in geriatric psychiatry
(2010) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2391
Fricke, M. (2021) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-8687
(2019) · doi:10.31038/asmhs.2019325
“The treatment and management of hypertension has been observed to slow cognitive decline in individuals with AD [27] and to reduce the risk of progression from MCI to AD Li et al.”
Background(2016) · Elsevier eBooks · doi:10.1016/b978-0-12-804538-1.00036-5
Lindemann, H. (2023) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-9889
Prediction of Dementia Onset using the Short-Term Memory Recall TestPreprint
Oshiyama, C., Kobayashi, N., Nishimura, T., & Niwa, S. (2024) · Research Square · doi:10.21203/rs.3.rs-4935873/v1
Clinical Antiaging Medicine: Antiaging Medicine from the Perspective of the Brain and Nervous System
Yamashita, T. (2024) · Springer eBooks · doi:10.1007/978-981-97-8514-8_70
Hu, J., Lu, S., Zhang, Q., Rehman, H., Zhu, C., Farrell, J. J., Au, R., Farrer, L. A., Qiu, W. Q., Chen, J., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5272191
Cognition, Diagnosis, and Treatment of Alzheimer’s Disease: A Review
Qin, Y., Deng, X., & Zhang, S. (2025) · Recent Patents on Biotechnology · doi:10.2174/0118722083358924250606173812
König, M. (2025) · VPT Magazin · doi:10.1055/s-0045-1812831
“Patient*innen, bei denen einige, aber nicht alle vaskulären Risiko faktoren behandelt wurden, wiesen eine mittlere Verschlechte rung auf [10].”
Petek, B., Häbel, H., Xu, H., Villa‐Lopez, M., Kalar, I., Hoang, M. T., Maioli, S., Pereira, J. B., Mostafaei, S., Winblad, B., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24873040
Herrero, N. R. (2022) · Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona)
Cerebrovascular Disease in Persons With Diabetes
Erbguth, F. J. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00023-9
Cognitive Aging : Role of Cardiovascular Disease Risk Factors
Kaffashian, S. (2013) · theses.fr (ABES) · doi:10.70675/2c3449d6z9b4cz4890z8899z3de15c339140
Clinical aspects of cerebral small vessel disease
Pantoni, L., & Gorelick, P. B. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781139382694.019
Metadata
- Authors
- Deschaintre, Y., Richard, F., Leys, D., & Pasquier, F.
- Affiliations
- Inserm (FR)
- Venue
- Neurology
- Published
- 2009-09
- Volume
- 73
- Issue
- 9
- Pages
- 674-680
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W1986968958
- Cited by
- 232
- References
- 38
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 8 · 2023: 10 · 2022: 6 · 2021: 11 · 2020: 11 · 2019: 17 · 2018: 8 · 2017: 14 · 2016: 16 · 2015: 17 · 2014: 18 · 2013: 16 · 2012: 22
- FWCI
- 15.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
- Keywords
- Alzheimer's disease, vascular risk factors, cognitive decline, dyslipidemia, diabetes mellitus, smoking, atherosclerosis, cerebrovascular disease, Mini-Mental State Examination, dementia prevention, secondary prevention
- MeSH terms
- Aged, Alzheimer Disease, Hypolipidemic Agents, Cerebral Arteries, Intracranial Arteriosclerosis, Cerebrovascular Disorders, Female, Humans, Longitudinal Studies, Male, Neuropsychological Tests, Risk Factors, Risk Management, Time, Time Factors, Disease Progression, Risk Reduction Behavior
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.